医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2015年
1期
87-89
,共3页
刘利利%王玫%任景芳%刘霞%徐纯香%赵薇
劉利利%王玫%任景芳%劉霞%徐純香%趙薇
류리리%왕매%임경방%류하%서순향%조미
亮丙瑞林/类似物和衍生物%亮丙瑞林/治疗应用%子宫内膜异位症/并发症%不育,女(雌)性/并发症%受精,体外
亮丙瑞林/類似物和衍生物%亮丙瑞林/治療應用%子宮內膜異位癥/併髮癥%不育,女(雌)性/併髮癥%受精,體外
량병서림/유사물화연생물%량병서림/치료응용%자궁내막이위증/병발증%불육,녀(자)성/병발증%수정,체외
Leuprolide/AA%Leuprolide/TU%Endometriosis/CO%Infertility,Female/CO%Fer-tilization in Vitro
目的观察注射用醋酸亮丙瑞林微球(贝依)治疗子宫腺肌病合并不孕的临床效果。方法对因子宫腺肌病合并不孕接受贝依超促排卵后,行体外受精‐胚胎移植(IVF‐ET )治疗的60例患者(观察组)的临床资料进行回顾性分析,另选取同期因输卵管因素及其他原因不孕行IVF‐ET治疗的子宫正常者60例作为对照组,记录观察组经贝依(3.75 mg/次,每28天1次)治疗后子宫体积的变化,并比较两组患者IVF‐ET结局。结果①观察组经过2~6次的贝依治疗后,子宫体积由治疗前的(178±75)cm3缩小至治疗后的(85±66)cm3,差异有统计学意义( P <0.05)。② IVF‐ET 结局:观察组的胚胎种植率(38.8%)、临床妊娠率(53.5%)和流产率(4.3%)与对照组相比(分别为35.3%,52.8%,3.6%)差异无显著性(均 P >0.05)。③观察组患者经IVF‐ET治疗后妊娠成功者的受精率(76.1%)、双原核率(67.8%)及优质胚胎率(63.4%)均高于妊娠失败者(分别为61.4%、60.8%、50.5%),差异均有统计学意义( P <0.05)。结论贝依能显著缩小子宫腺肌病患者的子宫体积,对合并不孕行IVF‐ET治疗的患者,经治疗后能够获得理想的助孕结局。
目的觀察註射用醋痠亮丙瑞林微毬(貝依)治療子宮腺肌病閤併不孕的臨床效果。方法對因子宮腺肌病閤併不孕接受貝依超促排卵後,行體外受精‐胚胎移植(IVF‐ET )治療的60例患者(觀察組)的臨床資料進行迴顧性分析,另選取同期因輸卵管因素及其他原因不孕行IVF‐ET治療的子宮正常者60例作為對照組,記錄觀察組經貝依(3.75 mg/次,每28天1次)治療後子宮體積的變化,併比較兩組患者IVF‐ET結跼。結果①觀察組經過2~6次的貝依治療後,子宮體積由治療前的(178±75)cm3縮小至治療後的(85±66)cm3,差異有統計學意義( P <0.05)。② IVF‐ET 結跼:觀察組的胚胎種植率(38.8%)、臨床妊娠率(53.5%)和流產率(4.3%)與對照組相比(分彆為35.3%,52.8%,3.6%)差異無顯著性(均 P >0.05)。③觀察組患者經IVF‐ET治療後妊娠成功者的受精率(76.1%)、雙原覈率(67.8%)及優質胚胎率(63.4%)均高于妊娠失敗者(分彆為61.4%、60.8%、50.5%),差異均有統計學意義( P <0.05)。結論貝依能顯著縮小子宮腺肌病患者的子宮體積,對閤併不孕行IVF‐ET治療的患者,經治療後能夠穫得理想的助孕結跼。
목적관찰주사용작산량병서림미구(패의)치료자궁선기병합병불잉적림상효과。방법대인자궁선기병합병불잉접수패의초촉배란후,행체외수정‐배태이식(IVF‐ET )치료적60례환자(관찰조)적림상자료진행회고성분석,령선취동기인수란관인소급기타원인불잉행IVF‐ET치료적자궁정상자60례작위대조조,기록관찰조경패의(3.75 mg/차,매28천1차)치료후자궁체적적변화,병비교량조환자IVF‐ET결국。결과①관찰조경과2~6차적패의치료후,자궁체적유치료전적(178±75)cm3축소지치료후적(85±66)cm3,차이유통계학의의( P <0.05)。② IVF‐ET 결국:관찰조적배태충식솔(38.8%)、림상임신솔(53.5%)화유산솔(4.3%)여대조조상비(분별위35.3%,52.8%,3.6%)차이무현저성(균 P >0.05)。③관찰조환자경IVF‐ET치료후임신성공자적수정솔(76.1%)、쌍원핵솔(67.8%)급우질배태솔(63.4%)균고우임신실패자(분별위61.4%、60.8%、50.5%),차이균유통계학의의( P <0.05)。결론패의능현저축소자궁선기병환자적자궁체적,대합병불잉행IVF‐ET치료적환자,경치료후능구획득이상적조잉결국。
[Objective] To observe the clinical efficacies of leuprorelin acetate microspheres for uterine ade‐nomyosis with infertility .[Methods] A total of 60 infertile patients with uterine adenomyosis (observation group) undergoing in vitro fertilization embryo transplant (IVF‐ET) ovum induction after using leuprorelin ac‐etate microspheres were studied retrospectively .Another 60 infertile patients with tubal factors were enrolled as control group .The volumes of uterus and outcomes of IVF‐ET were compared between two groups .[Re‐sults] ① Volume of uterus :In observation group after 2~6 courses of therapy (3 .75 mg/28 days) ,the mean uterine volume shrank from (178 ± 75) to (85 ± 66) cm3 ( P <0 .05);② Outcome of IVF‐ET :The rate of embryo implantation ,clinical pregnancy and abortion between observation group (38 .8% ,53 .5% ,4 .3% ) and control group (35 .3% ,52 .8% ,3 .6% ) had no significant difference ( P > 0 .05);③ In observation group ,the rate of fertilization ,two pronuclear and superior embryo in patients with successful pregnancy (76 .1% ,67 .8% ,63 .4% ) after IVF‐ET were higher than those with failed pregnancy (61 .4% ,60 .8% , 50 .5% ) .[Conclusion] Leuprorelin acetate microspheres may shrink the volume of uterine adenomyosis and improve the outcomes of pregnancy in patients undergoing IVF‐ET .